West Pharmaceutical Completes SmartDose System Transfer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: PRnewswire
- Transaction Completion: West Pharmaceutical Services successfully completed the sale and transfer of manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System on July 1, 2026, indicating a strategic shift in its injectable drug management approach.
- Ongoing Development: Despite the transfer of certain manufacturing rights, West will continue to develop and manufacture other versions of SmartDose, including the 10mL On-Body Delivery System, ensuring its competitive edge and technological innovation in the market.
- Market Position: In fiscal year 2025, West generated $3.07 billion in net sales, leveraging over 10,000 employees across 50 locations to provide high-quality injectable solutions, thereby solidifying its leadership position in the industry.
- Industry Impact: This transaction not only optimizes the company's product portfolio but may also provide funding for future technological research and market expansion, further enhancing its influence in the global pharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to fall
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 356.080
Low
285.00
Averages
348.70
High
375.00
Current: 356.080
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
West Pharmaceutical Services Stock Stages Strong Comeback
- Significant Stock Rebound: In 2026, West Pharmaceutical Services' stock has risen 32.9% year-to-date, significantly outperforming the industry's 30.3% decline and the S&P 500's 28.2% increase, reflecting a recovery in investor confidence.
- Strong Earnings Drive: The company reported first-quarter revenues of $845 million, a 21% year-over-year increase, with adjusted EPS soaring 47%, prompting management to raise full-year guidance, indicating robust demand in biologics and GLP-1 therapies.
- Biologics Business Growth: The biologics-related business achieved 26% organic growth in the first quarter, benefiting from the widespread adoption of NovaPure packaging solutions, suggesting long-term growth potential in the high-value product sector.
- Regulatory Demand Boost: The implementation of European Annex 1 sterile manufacturing regulations led to a 66% year-over-year increase in related projects, expected to contribute approximately 200 basis points to 2026 revenues, further supporting the company's margin expansion.
See More
West Pharmaceutical Completes SmartDose System Transfer
- Transaction Completion: West Pharmaceutical Services successfully completed the sale and transfer of manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System on July 1, 2026, indicating a strategic shift in its injectable drug management approach.
- Ongoing Development: Despite the transfer of certain manufacturing rights, West will continue to develop and manufacture other versions of SmartDose, including the 10mL On-Body Delivery System, ensuring its competitive edge and technological innovation in the market.
- Market Position: In fiscal year 2025, West generated $3.07 billion in net sales, leveraging over 10,000 employees across 50 locations to provide high-quality injectable solutions, thereby solidifying its leadership position in the industry.
- Industry Impact: This transaction not only optimizes the company's product portfolio but may also provide funding for future technological research and market expansion, further enhancing its influence in the global pharmaceutical sector.
See More
Market Capitalization Comparison: Southwest Airlines vs. West Pharmaceutical
- Market Cap Comparison: Southwest Airlines has a market capitalization of $24.90 billion, while West Pharmaceutical Services stands at $24.05 billion, highlighting their relative sizes in the market, which may influence investor choices and fund flows.
- Investor Misconception: Many novice investors mistakenly believe that a higher stock price indicates greater company value, but market capitalization provides a more accurate comparison of company worth, aiding investors in making informed decisions.
- Market Impact: The size of a company's market cap directly affects which mutual funds and ETFs are willing to hold these stocks, particularly as large-cap funds tend to focus on companies valued over $10 billion, influencing capital inflows and outflows.
- Index Classification: For instance, the S&P MidCap index focuses on smaller companies by excluding the largest 100 firms, indicating the significance of market cap in company classification and investment strategies, potentially allowing smaller firms to outperform larger ones in favorable market conditions.
See More
Strong Cash Flow Investment Opportunities Identified
- RTX Investment Risks: Raytheon (RTX) has a trailing 12-month free cash flow margin of 9.4%, with an estimated sales growth of only 5.9% for the next 12 months, indicating a slowdown in demand, while management struggles to find profitable growth opportunities, resulting in a high valuation ratio of 26.3x.
- WST Profitability Decline: West Pharmaceutical Services (WST) shows a trailing 12-month free cash flow margin of 14.2%, but its annual growth rate of 4.9% falls below industry averages, and its adjusted operating margin has decreased by 5.8 percentage points over the past five years, indicating increased competition is eroding profitability, with a current stock price of $336.34 and a P/E ratio of 37.8x.
- ROAD Investment Outlook: Construction Partners (ROAD) boasts a trailing 12-month free cash flow margin of 6.7%, with an impressive annual revenue growth rate of 39.9%, indicating significant market share gains, while its annual earnings per share growth of 46.7% outpaces revenue performance, trading at $123.14 per share with a P/E of 39.8x, showcasing strong profitability.
- Market Potential Analysis: While RTX and WST face risks of slowing growth and declining profitability, ROAD's robust financial performance and market share growth position it as a potential stock of interest for investors, suggesting a focus on its future performance.
See More
Cardinal Health Continues Growth with Stock Price Surge
- Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
- Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
- Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
- Rapid Expansion of New Businesses: The company's
See More
US Stocks Close: Nasdaq Hits 5-Week Low Amid Market Rotations
- Market Volatility: The S&P 500 index fell by 0.26% and the Nasdaq 100 dropped by 1.12% on Tuesday, indicating a shift to a downward trend after an early advance, reflecting investor concerns over tech stocks.
- Energy Price Impact: WTI crude oil prices plunged by 3% to a seven-week low, leading to widespread declines in energy producers' stocks, which exacerbated the overall market weakness and highlighted the direct impact of oil price fluctuations on related sectors.
- Real Estate Market Recovery: US existing home sales rose to 4.17 million in April, a five-month high, boosting the stocks of builders and suppliers, indicating that a recovery in the real estate market could provide positive signals for the economy.
- International Trade Data Improvement: China's May exports increased by 19.4% year-on-year, surpassing expectations, showcasing potential for global economic growth, which may positively influence the US market, despite ongoing uncertainties.
See More
West Pharmaceutical Services Stock Stages Strong Comeback
- Significant Stock Rebound: In 2026, West Pharmaceutical Services' stock has risen 32.9% year-to-date, significantly outperforming the industry's 30.3% decline and the S&P 500's 28.2% increase, reflecting a recovery in investor confidence.
- Strong Earnings Drive: The company reported first-quarter revenues of $845 million, a 21% year-over-year increase, with adjusted EPS soaring 47%, prompting management to raise full-year guidance, indicating robust demand in biologics and GLP-1 therapies.
- Biologics Business Growth: The biologics-related business achieved 26% organic growth in the first quarter, benefiting from the widespread adoption of NovaPure packaging solutions, suggesting long-term growth potential in the high-value product sector.
- Regulatory Demand Boost: The implementation of European Annex 1 sterile manufacturing regulations led to a 66% year-over-year increase in related projects, expected to contribute approximately 200 basis points to 2026 revenues, further supporting the company's margin expansion.
See More
West Pharmaceutical Completes SmartDose System Transfer
- Transaction Completion: West Pharmaceutical Services successfully completed the sale and transfer of manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System on July 1, 2026, indicating a strategic shift in its injectable drug management approach.
- Ongoing Development: Despite the transfer of certain manufacturing rights, West will continue to develop and manufacture other versions of SmartDose, including the 10mL On-Body Delivery System, ensuring its competitive edge and technological innovation in the market.
- Market Position: In fiscal year 2025, West generated $3.07 billion in net sales, leveraging over 10,000 employees across 50 locations to provide high-quality injectable solutions, thereby solidifying its leadership position in the industry.
- Industry Impact: This transaction not only optimizes the company's product portfolio but may also provide funding for future technological research and market expansion, further enhancing its influence in the global pharmaceutical sector.
See More
Market Capitalization Comparison: Southwest Airlines vs. West Pharmaceutical
- Market Cap Comparison: Southwest Airlines has a market capitalization of $24.90 billion, while West Pharmaceutical Services stands at $24.05 billion, highlighting their relative sizes in the market, which may influence investor choices and fund flows.
- Investor Misconception: Many novice investors mistakenly believe that a higher stock price indicates greater company value, but market capitalization provides a more accurate comparison of company worth, aiding investors in making informed decisions.
- Market Impact: The size of a company's market cap directly affects which mutual funds and ETFs are willing to hold these stocks, particularly as large-cap funds tend to focus on companies valued over $10 billion, influencing capital inflows and outflows.
- Index Classification: For instance, the S&P MidCap index focuses on smaller companies by excluding the largest 100 firms, indicating the significance of market cap in company classification and investment strategies, potentially allowing smaller firms to outperform larger ones in favorable market conditions.
See More
Strong Cash Flow Investment Opportunities Identified
- RTX Investment Risks: Raytheon (RTX) has a trailing 12-month free cash flow margin of 9.4%, with an estimated sales growth of only 5.9% for the next 12 months, indicating a slowdown in demand, while management struggles to find profitable growth opportunities, resulting in a high valuation ratio of 26.3x.
- WST Profitability Decline: West Pharmaceutical Services (WST) shows a trailing 12-month free cash flow margin of 14.2%, but its annual growth rate of 4.9% falls below industry averages, and its adjusted operating margin has decreased by 5.8 percentage points over the past five years, indicating increased competition is eroding profitability, with a current stock price of $336.34 and a P/E ratio of 37.8x.
- ROAD Investment Outlook: Construction Partners (ROAD) boasts a trailing 12-month free cash flow margin of 6.7%, with an impressive annual revenue growth rate of 39.9%, indicating significant market share gains, while its annual earnings per share growth of 46.7% outpaces revenue performance, trading at $123.14 per share with a P/E of 39.8x, showcasing strong profitability.
- Market Potential Analysis: While RTX and WST face risks of slowing growth and declining profitability, ROAD's robust financial performance and market share growth position it as a potential stock of interest for investors, suggesting a focus on its future performance.
See More
Cardinal Health Continues Growth with Stock Price Surge
- Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
- Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
- Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
- Rapid Expansion of New Businesses: The company's
See More
US Stocks Close: Nasdaq Hits 5-Week Low Amid Market Rotations
- Market Volatility: The S&P 500 index fell by 0.26% and the Nasdaq 100 dropped by 1.12% on Tuesday, indicating a shift to a downward trend after an early advance, reflecting investor concerns over tech stocks.
- Energy Price Impact: WTI crude oil prices plunged by 3% to a seven-week low, leading to widespread declines in energy producers' stocks, which exacerbated the overall market weakness and highlighted the direct impact of oil price fluctuations on related sectors.
- Real Estate Market Recovery: US existing home sales rose to 4.17 million in April, a five-month high, boosting the stocks of builders and suppliers, indicating that a recovery in the real estate market could provide positive signals for the economy.
- International Trade Data Improvement: China's May exports increased by 19.4% year-on-year, surpassing expectations, showcasing potential for global economic growth, which may positively influence the US market, despite ongoing uncertainties.
See More
